Overview

Golcadomide and Nivolumab in Patients With Non-Hodgkin Lymphoma With Refractory Disease After Chimeric Antigen T-cell Therapy

Status:
NOT_YET_RECRUITING

Trial end date:
2028-04-30

Target enrollment:

Participant gender:

Summary

In this combined phase I/II, open label, single arm trial to study, the safety and efficacy of combination Golcadomide and nivolumab in patients with non-Hodgkin lymphoma (NHL) who have experienced refractory/residual disease, at or after 30 days of receiving chimeric antigen T-cell (CAR-T) therapy will be studied. A dose escalation phase will be followed by a dose expansion design.

Phase:

PHASE1

Details

Lead Sponsor:

Natalie Galanina

Collaborator:

Bristol-Myers Squibb

Treatments:

Nivolumab